In Brief
This article was originally published in The Tan Sheet
Executive Summary
CHPA defends phytosterol claim
You may also be interested in...
Valeant Deal Would Aid Afexa’s Cold-FX Expansion Plans
Valeant Pharmaceuticals International’s acquisition of Afexa Health Sciences likely will boost efforts to transition Afexa’s Cold-FX from a Canadian natural health product to a U.S. pharmaceutical.
FDA Extends Enforcement Discretion On Free Phytosterol Health Claims
FDA will give firms a year to relabel or reformulate dietary supplements with nonesterified phytosterols to comply with a proposed rule that overhauls a health claim linking phytosterols to a reduced risk of coronary heart disease.
Limit On Phytosterol CHD Health Claim Would Disrupt Industry – Cargill
Dietary supplement industry stakeholders "urgently" ask FDA to continue allowing coronary heart disease reduction health claims for supplements with nonesterified phytosterols, or risk "irreparable injury" to some firms.